Potassium canrenoate
From Wikipedia, the free encyclopedia
|
Potassium canrenoate
|
|
| Systematic (IUPAC) name | |
| potassium 3-[(8R,9S,10R,13S,14S,17R)- 17-hydroxy-10,13-dimethyl-3-oxo-2,8,9, 11,12,14,15,16-octahydro-1H-cyclopenta[a] phenanthren-17-yl]propanoate |
|
| Identifiers | |
| CAS number | ? |
| ATC code | C03 |
| PubChem | |
| Chemical data | |
| Formula | C22H29KO4 |
| Mol. mass | 369.516 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | ? |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Potassium canrenoate (INN) or canrenoate potassium (USAN), the potassium salt of canrenoic acid, is an aldosterone antagonist.
Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
[edit] See also
|
||||||||||||||||||||

